je.st
news
Phase III data show investigational compound empagliflozin...
2013-06-22 19:08:23| Biotech - Topix.net
In the pooled analysis, presented at the American Diabetes Association 73rd Scientific SessionsA , people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose , weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an ... (more)
Tags: show
data
iii
phase
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||